ANI Pharmaceuticals Inc (NASDAQ:ANIP) — Market Cap & Net Worth
Market Cap & Net Worth: ANI Pharmaceuticals Inc (ANIP)
ANI Pharmaceuticals Inc (NASDAQ:ANIP) has a market capitalization of $1.80 Billion ($1.80 Billion) as of May 2, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #6672 globally and #1956 in its home market, demonstrating a 2.98% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ANI Pharmaceuticals Inc's stock price $80.39 by its total outstanding shares 22414104 (22.41 Million). Analyse ANIP cash flow conversion to see how efficiently the company converts income to cash.
ANI Pharmaceuticals Inc Market Cap History: 2015 to 2026
ANI Pharmaceuticals Inc's market capitalization history from 2015 to 2026. Data shows growth from $1.01 Billion to $1.80 Billion (6.39% CAGR).
Index Memberships
ANI Pharmaceuticals Inc is a constituent of 4 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.07% | #167 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #712 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.67 Trillion | 0.11% | #107 of 263 |
|
S&P Small-Cap 600 Index
SML
|
$1.54 Trillion | 0.09% | #337 of 602 |
Weight: ANI Pharmaceuticals Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
ANI Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ANI Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
2.00x
ANI Pharmaceuticals Inc's market cap is 2.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
22.59x
ANI Pharmaceuticals Inc's market cap is 22.59 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.36 Billion | $128.62 Million | $3.93 Million | 10.56x | 345.38x |
| 2017 | $1.44 Billion | $176.84 Million | -$1.08 Million | 8.17x | N/A |
| 2018 | $1.01 Billion | $201.58 Million | $15.49 Million | 5.01x | 65.13x |
| 2019 | $1.38 Billion | $206.55 Million | $6.09 Million | 6.69x | 226.83x |
| 2020 | $650.91 Million | $208.47 Million | -$22.55 Million | 3.12x | N/A |
| 2021 | $1.03 Billion | $216.14 Million | -$42.60 Million | 4.78x | N/A |
| 2022 | $901.72 Million | $316.38 Million | -$47.90 Million | 2.85x | N/A |
| 2023 | $1.24 Billion | $486.82 Million | $18.78 Million | 2.54x | 65.81x |
| 2024 | $1.24 Billion | $614.38 Million | -$18.52 Million | 2.02x | N/A |
| 2025 | $1.77 Billion | $883.37 Million | $78.34 Million | 2.00x | 22.59x |
Competitor Companies of ANIP by Market Capitalization
Companies near ANI Pharmaceuticals Inc in the global market cap rankings as of May 2, 2026.
Key companies related to ANI Pharmaceuticals Inc by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #499 globally with a market cap of $52.60 Billion USD.
- Zoetis Inc (NYSE:ZTS): Ranked #525 globally with a market cap of $50.31 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #526 globally with a market cap of $50.29 Billion USD ( CN¥343.70 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #572 globally with a market cap of $45.88 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #499 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #525 | Zoetis Inc | NYSE:ZTS | $50.31 Billion | $114.16 |
| #526 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.29 Billion | CN¥53.88 |
| #572 | GALDERMA GROUP AG | NYSE:GALDY | $45.88 Billion | $42.09 |
ANI Pharmaceuticals Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, ANI Pharmaceuticals Inc's market cap moved from $1.01 Billion to $ 1.80 Billion, with a yearly change of 6.39%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.80 Billion | +1.84% |
| 2025 | $1.77 Billion | +42.80% |
| 2024 | $1.24 Billion | +0.25% |
| 2023 | $1.24 Billion | +37.06% |
| 2022 | $901.72 Million | -12.70% |
| 2021 | $1.03 Billion | +58.68% |
| 2020 | $650.91 Million | -52.91% |
| 2019 | $1.38 Billion | +36.98% |
| 2018 | $1.01 Billion | -30.15% |
| 2017 | $1.44 Billion | +6.32% |
| 2016 | $1.36 Billion | +34.34% |
| 2015 | $1.01 Billion | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of ANI Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.80 Billion USD |
| MoneyControl | $1.80 Billion USD |
| MarketWatch | $1.80 Billion USD |
| marketcap.company | $1.80 Billion USD |
| Reuters | $1.80 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About ANI Pharmaceuticals Inc
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and pote… Read more